Sera Prognostics (SERA) Q2 FY26 earnings call

Sera Prognostics achieved significant milestones in Q2 FY26, securing Illinois Medicaid coverage and expanding payer engagement, validating the PreTRM Test's clinical and economic value. While revenue remains modest and net loss increased, the company is building foundational elements for broad adoption, including clinical validation and commercial execution, with a strong cash position to fund operations through 2029. The focus is now shifting from securing access to driving utilization and implementation in priority markets.